Filing Flows › Precision Biosciences (DTIL) › Guidance & outlook
Precision Biosciences (DTIL) guidance and outlook
Precision Biosciences (DTIL) gave its guidance on Nov 3, 2026: Revenue (segment) $100K for FY2026.
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $100K | new |
From the earnings release filed Nov 3, 2026 (8-K on EDGAR).
Precision Biosciences' latest quarter
Precision Biosciences, Q3 FY26: revenue $10.8M (374× year over year), operating margin -83.7%, net loss $18.4M, operating cash flow −$11.9M. The chart follows the revenue to costs, profit and cash.
Questions
Did Precision Biosciences raise or lower its guidance?
Precision Biosciences (DTIL) gave its guidance on Nov 3, 2026: Revenue (segment) $100K for FY2026.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.